Longtime activist investor George Armoyan is unhappy with debentures that a Toronto-based real estate investment trust is issuing as part of a move to buy a suburban Chicago office tower occupied by global pharmaceutical giant Pfizer.
Longtime activist investor George Armoyan is unhappy with debentures that a Toronto-based real estate investment trust is issuing as part of a move to buy a suburban Chicago office tower occupied by global pharmaceutical giant Pfizer.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
Real Estate